On Monday, nearly a dozen drugmakers are set to finalize agreements with President Trump to voluntarily lower their medication prices, as reported by MS NOW.
This initiative is part of Trump's broader strategy to link U.S. drug prices to those in other countries, a move that has already seen 17 pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk, engage in similar agreements under the 'most favored nation' policy. Trump is expected to announce these developments at 3:00 p.m. ET.
The new deals are anticipated to provide discounts on outpatient drugs to state Medicaid programs, potentially aligning U.S. prices with those charged in foreign markets. However, participation by state Medicaid programs is optional, and the impact on out-of-pocket costs for patients remains uncertain.
The 'most favored nation' agreements have already influenced the commercial strategies and financial performance of major pharmaceutical firms, prompting them to invest heavily in U.S. manufacturing and expand direct-to-consumer sales channels.
Despite these efforts, companies like Novo Nordisk have indicated that lower U.S. prices are affecting their revenue, as prescription volumes may take time to recover. A 2024 Rand Corp. study highlighted that U.S. drug prices are nearly three times higher than those abroad, with branded drugs costing over four times more.
The pharmaceutical trade association PhRMA has criticized the 'most favored nation' approach, suggesting that it may not be the most effective way to reduce drug costs, instead pointing to pharmacy benefit managers as a key factor in price disparities.
The U.S. market remains crucial for many drugmakers, including European companies, which derive a significant portion of their sales from American consumers